At a glance
ClinicalIndex Comparison Record- ✓Locally advanced or metastatic and/or unresectable HCC confirmed by histology/cytology or clinically by AASLD criteria in cirrhotic participants
- ✓Disease not amenable to curative surgical and/or locoregional therapies
- ✓No prior systemic treatment for locally advanced or metastatic and/or unresectable HCC
- ✓Measurable disease with at least one untreated target lesion per RECIST v1.1
- ✕Pregnancy or breastfeeding
- ✕Prior treatment with CD137 agonists or immune checkpoint blockade therapies
- ✕Treatment with investigational therapy within 28 days prior to initiation of study treatment
- ✕Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-label, Multi-cohort, Multicenter Study in Patients With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
In Brief
A Phase 2 clinical trial evaluating Atezolizumab and Bevacizumab for Hepatocellular Carcinoma. Currently recruiting, targeting 30 participants across 62 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
Study Details
Timeline
Arms & Interventions
Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator.
Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator.
Interventions
Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) by IV infusion on Day 1 of each 21-day cycle.